Sera Prognostics reports Q4 EPS (16c), consensus (19c)

Reports Q4 revenue $10K vs. $24K last year. In February 2025, Sera completed an underwritten public offering of common stock and pre-funded warrants extending cash runway through 2028. “2025 marked a pivotal year for Sera as we moved from clinical validation to commercial execution,” said Zhenya Lindgardt, CEO. “The publication of the landmark PRIME Study delivered strong, peer-reviewed evidence that the PreTRM Test improves outcomes and reduces costs, creating a compelling value proposition for payers. During the year we expanded engagement across our target states, advanced active discussions with both commercial and Medicaid payers, and invested deliberately in leadership, access and infrastructure to support us as we scale. With a strengthened balance sheet, extending our runway through 2028, we enter 2026 focused on converting this foundation into broader adoption, payer coverage, and measurable impact for the families we serve.”